SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE.X is trending as the community rallies around the meme coin, expressing bullish sentiment and encouraging others to join before a potential surge. Talk centers on community growth, relentless promotion, and the expectation of significant gains. The coin's association with the popular "Rage Guy" meme and potential listing on major exchanges are also fueling excitement.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community celebrates its joke-inspired roots and long-term presence on the Solana blockchain. Many are drawn to its dedicated community, locked liquidity, and association with the popular "What's UpDog?" meme, while others highlight its potential within the broader meme coin landscape.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics ($CVKD) is trending as traders discuss its bullish technical setup and potential for an upside breakout, fueled by recent news of the acquisition of anti-coagulant assets. The community highlights the momentum and strong buyer confidence, while also noting the healthcare technology niche and upcoming milestones for their drug Tecarfarin. Some are watching for volume to confirm the move, and analysts are noting high price targets for the stock.

Codatta

Codatta ($XNY.X) is trending amid discussions about its on-chain fingerprint verification launch and potential applications of its AI/data utility. The community is analyzing its chart patterns, with some pointing to bullish setups and expecting new highs, while others are watching key support levels for potential entry points. Sentiment is mixed, with some expressing excitement about its potential and others remaining cautious.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive (DRV.X) is trending as the community discusses its strong chart and potential for another leg up, with some highlighting treasury loop mechanisms like airdrops and buybacks. The community also notes ongoing consolidation and recent upward movement, with some suggesting potential buybacks are underway. Furthermore, the community is discussing the partnership of Synthetix and Derive to build derivatives on ETH L1.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is trending due to unusual options activity signaling bullish sentiment and actionable alerts for call options, driving speculative interest. The community is also discussing the company's resilience amid volatile oil prices, strong balance sheet, and potential upside from the Marathon Oil acquisition. Discussions also include ConocoPhillips' LNG deals and analysts weighing in on the company's strengths and weaknesses compared to its peers.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals ($ENTA) is trending due to topline results from its Phase 2b study, with community members eagerly awaiting further details. Some speculate on the potential for significant gains depending on the results, especially related to viral load reduction. The company's work on zelicapavir, an oral RSV N-protein inhibitor, is also drawing attention, particularly its potential in the adult RSV therapeutics market.

Pangolin is a community-driven decentralized exchange for Avalanche and Ethereum assets with fast settlement, low transaction fees, and a democratic distribution–powered by Avalanche.

Pangolin

Pangolin crypto is trending amidst mixed sentiments; while some traders express excitement about potential breakouts and the upcoming V3 launch, others are calling it a scam coin, citing concerns about the project's fundamentals and past performance. The community is actively discussing potential price movements and whether it's time to buy or sell, with some highlighting its limited supply as a positive factor.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol ($ASM.X) is trending as traders discuss potential catalysts, including possible exchange listings and movements by large Asian investors. Some community members express optimism for a pump, citing the low market cap, while others remain cautious, pointing to past volatility and dilution concerns. Conversations also mention Assemble Protocol's AI integration and potential partnerships, with some hoping for a significant price increase soon.

Bilibili, Inc. is a holding company, which engages in the provision of online entertainment content. The firm enables broad video-based content consumption scenarios centered around professional user generated videos supplemented with live broadcasting, occupationally generated videos, or occupationally generated videos. The company was founded by Xu Yi in June 2009 and is headquartered Shanghai, China.

Bilibili Inc - ADR

BILIBILI INC.

BILI is trending as the community discusses its long-term chart accumulation and potential breakout, fueled by bullish sentiment towards Chinese companies and recent bullish call sweeps. Some traders are eyeing it as the next big China runner, while others point to technical indicators and monetization struggles. Discussions also include overnight trading activity and potential gap-ups.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter picked up around Vanda Pharmaceuticals on Thursday after the company formally asked U.S. Food and Drug Administration (FDA) Commissioner Martin Makary to review a decision upholding the approval of two generic versions of its sleep drug Hetlioz, intensifying its fight with regulators just days after winning a separate court battle.In a filing, Vanda said it wants Makary to examine the ruling issued in July by Jacqueline Corrigan-Curay, the outgoing director of the FDA’s Center for Drug Evaluation and Research (CDER).&nbsp;Her decision, made shortly before her retirement, sided with the Office of Generic Drugs in clearing two competing versions of Hetlioz despite what Vanda argues were “significant flaws” in the underlying studies.The company said regulators accepted bioequivalence studies conducted only in Indian male subjects and overlooked data inconsistencies, including one generic that showed blood exposure levels more than twice those seen with Hetlioz.&nbsp;Vanda also criticized what it described as an entrenched FDA bias toward approving generics “regardless of whether they meet the requisite legal and evidentiary standards.”The latest push comes just days after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-cuts-ozempic-cost-to-499-dollars-per-month-for-self-paying-patients/chsOfKDRdXE">Vanda scored a legal win in Washington</a>, where a federal appeals court threw out the FDA’s rejection of Hetlioz as a jet lag treatment.&nbsp;The judges faulted the agency for giving the application only a cursory review and sent it back, saying the FDA must now either approve the drug for that use or give Vanda a proper hearing.&nbsp;The ruling revived a regulatory dispute dating back to 2018, when Vanda first sought approval for the indication.Hetlioz is already cleared in the U.S. to treat Non-24-Hour Sleep-Wake Disorder and sleep problems linked to Smith-Magenis Syndrome. It remains one of Vanda’s key products, generating $16.2 million in the second quarter of 2025, about 31% of the company’s revenue.Vanda said bureaucrats have indicated it may take up to two months for the FDA’s Office of the Commissioner to decide whether Makary himself will review the generics decision.&nbsp;“It is time that the rule of law return to the FDA under Dr. Makary’s leadership,” the company said in its statement.On Stocktwits, retail sentiment for Vanda was ‘bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/VNDA">Vanda’s stock</a> has declined nearly 6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Stocktwits, retail sentiment for Vanda (VNDA) was ‘bullish’ amid ‘high’ message volume. (Photo credit: Getty Images)

Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals”

The company argues that regulators relied on narrow study populations and overlooked major data inconsistencies, raising concerns about patient safety.

Equity

Vanda Pharmaceuticals Inc. (VNDA) shares surged 9% on Monday after the company said that a Federal Appeals Court overturned the U.S. Food and Drug Administration’s order denying approval to its drug Hetlioz in the treatment of jet lag disorder.Vanda had submitted its application to the FDA seeking approval for Hetlioz to treat jet lag disorder in October 2018. A federal district court ordered the FDA to resolve the application or commence a hearing with respect to the application after the agency delayed it. However, instead of holding a hearing, the agency issued an order refusing to approve the application, and Vanda subsequently filed a petition for review with the U.S. Court of Appeals for the D.C. Circuit.The appeals court set aside the FDA’s action and stated that the agency’s "treatment of Vanda's evidence is cursory," the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://vandapharmaceuticalsinc.gcs-web.com/node/16556/pdf">said</a> on Monday. The court has remanded the case back to the FDA, where Vanda expects the FDA will either approve the drug application or the company will receive a hearing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/VNDA">Vanda</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘low’ levels.&nbsp;<figure class="image"><img style="aspect-ratio:578/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_18_at_11_58_28_AM_png_ad9d75a67b.webp" alt="VNDA's Sentiment Meter and Message Volume as of 11:55 a.m. ET on Aug. 18, 2025 | Source: Stocktwits" width="578" height="63"><figcaption>VNDA's Sentiment Meter and Message Volume as of 11:55 a.m. ET on Aug. 18, 2025 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user expects the stock to hit over $5.<stembedurl>https://stocktwits.com/HorizonBull/message/625611441</stembedurl>Another opined that the legal turnaround is a “strongly bullish development” for Vanda.<stembedurl>https://stocktwits.com/BigSqueezeComing/message/625585269</stembedurl>Hetlioz is a prescription medicine approved to treat people with Non-24-Hour Sleep-Wake Disorder and to treat nighttime sleep disturbances in Smith-Magenis Syndrome (SMS).In the second quarter of 2025, Hetlioz's net sales were $16.2 million, accounting for nearly 31% of Vanda’s overall total revenues. VNDA stock is down by about 11% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-space-starlink-changes-to-south-africa-black-ownership-rules/chsOhmVRdXO">SpaceX Calls For Changes To South Africa’s Black Ownership Rules For Telecom Companies: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark 

The court has remanded the case back to the FDA, where Vanda expects the agency will either approve the drug application or the company will receive a hearing.

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?

Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Vanda Pharmaceuticals announces the publication of an article titled 'Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S' Vanda Pharmaceuticals announces the...

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire WASHINGTON, Feb. 13...

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on...

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist Vanda Pharmaceuticals and Anaptys Announce...

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

VNDA
Vanda Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VNDA News

VNDA Vanda Pharmaceuticals Inc